• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因组和糖酵解熵是非小细胞肺癌可靠的放射基因组异质性生物标志物。

Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer.

机构信息

Department of Nuclear Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.

School of Medicine, College of Medicine, Tzu Chi University, Hualien 97004, Taiwan.

出版信息

Int J Mol Sci. 2023 Feb 16;24(4):3988. doi: 10.3390/ijms24043988.

DOI:10.3390/ijms24043988
PMID:36835402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9959107/
Abstract

Radiogenomic heterogeneity features in F-fluorodeoxyglucose positron emission tomography (F-FDG PET) have become popular in non-small cell lung cancer (NSCLC) research. However, the reliabilities of genomic heterogeneity features and of PET-based glycolytic features in different image matrix sizes have yet to be thoroughly tested. We conducted a prospective study with 46 NSCLC patients to assess the intra-class correlation coefficient (ICC) of different genomic heterogeneity features. We also tested the ICC of PET-based heterogeneity features from different image matrix sizes. The association of radiogenomic features with clinical data was also examined. The entropy-based genomic heterogeneity feature (ICC = 0.736) is more reliable than the median-based feature (ICC = -0.416). The PET-based glycolytic entropy was insensitive to image matrix size change (ICC = 0.958) and remained reliable in tumors with a metabolic volume of <10 mL (ICC = 0.894). The glycolytic entropy is also significantly associated with advanced cancer stages ( = 0.011). We conclude that the entropy-based radiogenomic features are reliable and may serve as ideal biomarkers for research and further clinical use for NSCLC.

摘要

氟代脱氧葡萄糖正电子发射断层扫描(F-FDG PET)的放射基因组异质性特征在非小细胞肺癌(NSCLC)研究中已经很流行。然而,基因组异质性特征和不同图像矩阵大小的基于 PET 的糖酵解特征的可靠性尚未得到彻底测试。我们对 46 名 NSCLC 患者进行了一项前瞻性研究,以评估不同基因组异质性特征的组内相关系数(ICC)。我们还测试了来自不同图像矩阵大小的基于 PET 的异质性特征的 ICC。还检查了放射基因组特征与临床数据的相关性。基于熵的基因组异质性特征(ICC=0.736)比基于中位数的特征(ICC=-0.416)更可靠。基于 PET 的糖酵解熵对图像矩阵大小变化不敏感(ICC=0.958),并且在代谢体积<10mL 的肿瘤中仍然可靠(ICC=0.894)。糖酵解熵也与晚期癌症阶段显著相关(=0.011)。我们得出结论,基于熵的放射基因组特征是可靠的,可能是 NSCLC 研究和进一步临床应用的理想生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/0eac7dfc60e4/ijms-24-03988-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/18709ee2d771/ijms-24-03988-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/c95b59f29766/ijms-24-03988-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/e3952da31b2b/ijms-24-03988-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/0eac7dfc60e4/ijms-24-03988-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/18709ee2d771/ijms-24-03988-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/c95b59f29766/ijms-24-03988-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/e3952da31b2b/ijms-24-03988-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/456f/9959107/0eac7dfc60e4/ijms-24-03988-g004.jpg

相似文献

1
Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer.基因组和糖酵解熵是非小细胞肺癌可靠的放射基因组异质性生物标志物。
Int J Mol Sci. 2023 Feb 16;24(4):3988. doi: 10.3390/ijms24043988.
2
Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.肿瘤内18F-FDG摄取异质性降低了正电子发射断层扫描/计算机断层扫描成像在靶体积定义上的可靠性。
J Med Imaging Radiat Oncol. 2015 Jun;59(3):338-45. doi: 10.1111/1754-9485.12289. Epub 2015 Feb 23.
3
Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.非小细胞肺癌中静态与参数化18F-FDG PET图像肿瘤摄取异质性特征的比较
J Nucl Med. 2016 Jul;57(7):1033-9. doi: 10.2967/jnumed.115.166918. Epub 2016 Mar 10.
4
Potential advantages of FDG-PET radiomic feature map for target volume delineation in lung cancer radiotherapy.FDG-PET 放射组学特征图谱在肺癌放疗靶区勾画中的潜在优势。
J Appl Clin Med Phys. 2022 Sep;23(9):e13696. doi: 10.1002/acm2.13696. Epub 2022 Jun 14.
5
Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic F Fluorodeoxyglucose PET.利用动态 F 氟脱氧葡萄糖 PET 对非小细胞肺癌组织学亚型内葡萄糖代谢率进行肿瘤勾画和定量评估。
Radiology. 2017 May;283(2):547-559. doi: 10.1148/radiol.2016160329. Epub 2016 Nov 15.
6
Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.氟-18 氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(¹⁸F-FDG PET/CT)与肿瘤标志物联合诊断非小细胞肺癌(NSCLC)淋巴结转移:回顾性和前瞻性研究。
Med Sci Monit. 2020 Jun 2;26:e922675. doi: 10.12659/MSM.922675.
7
Heterogeneity in [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography of non-small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging.非小细胞肺癌[¹⁸F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的异质性及其与代谢参数和病理分期的关系。
Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00032.
8
Pretherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography robust radiomic features predict overall survival in non-small cell lung cancer.治疗前 18F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的稳健放射组学特征可预测非小细胞肺癌的总生存期。
Nucl Med Commun. 2022 May 1;43(5):540-548. doi: 10.1097/MNM.0000000000001541.
9
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability.FDG-PET 影像组学特征的稳定性:测试-重测和观察者间变异性的综合分析。
Acta Oncol. 2013 Oct;52(7):1391-7. doi: 10.3109/0284186X.2013.812798. Epub 2013 Sep 9.
10
18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.18F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)-非小细胞肺癌(NSCLC)转移淋巴结和原发肿瘤的放射组学——一项前瞻性外部验证研究。
PLoS One. 2018 Mar 1;13(3):e0192859. doi: 10.1371/journal.pone.0192859. eCollection 2018.

引用本文的文献

1
Insights into pet-based radiogenomics in oncology: an updated systematic review.肿瘤学中基于宠物的放射基因组学见解:最新系统综述
Eur J Nucl Med Mol Imaging. 2025 Apr 7. doi: 10.1007/s00259-025-07262-7.
2
The value of F-fluorodeoxyglucose positron emission tomography-based radiomics in non-small cell lung cancer.基于F-氟脱氧葡萄糖正电子发射断层扫描的影像组学在非小细胞肺癌中的价值
Tzu Chi Med J. 2024 Sep 3;37(1):17-27. doi: 10.4103/tcmj.tcmj_124_24. eCollection 2025 Jan-Mar.
3
The Ubiquitin-Proteasome System in Tumor Metabolism.肿瘤代谢中的泛素-蛋白酶体系统

本文引用的文献

1
Exploring biomarkers for prognosis and neoadjuvant chemosensitivity in rectal cancer: Multi-omics and ctDNA sequencing collaboration.探索直肠癌预后和新辅助化疗敏感性的生物标志物:多组学和 ctDNA 测序合作。
Front Immunol. 2022 Dec 9;13:1013828. doi: 10.3389/fimmu.2022.1013828. eCollection 2022.
2
The combined tumor-nodal glycolytic entropy improves survival stratification in nonsmall cell lung cancer with locoregional disease.联合肿瘤-淋巴结糖酵解熵可改善局部区域疾病非小细胞肺癌的生存分层。
Nucl Med Commun. 2023 Jan 1;44(1):100-107. doi: 10.1097/MNM.0000000000001645. Epub 2022 Nov 25.
3
Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma.
Cancers (Basel). 2023 Apr 20;15(8):2385. doi: 10.3390/cancers15082385.
突变等位基因肿瘤异质性,一种评估晚期肺腺癌肿瘤内异质性的有利生物标志物。
Front Oncol. 2022 Jul 1;12:888951. doi: 10.3389/fonc.2022.888951. eCollection 2022.
4
Role of fluorodeoxyglucose-positron emission tomography in predicting the pathological response and prognosis after neoadjuvant chemoradiotherapy for locally advanced non-small-cell lung cancer.氟脱氧葡萄糖正电子发射断层扫描在预测局部晚期非小细胞肺癌新辅助放化疗后的病理反应和预后中的作用。
Interact Cardiovasc Thorac Surg. 2022 Jul 9;35(2). doi: 10.1093/icvts/ivac113.
5
HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.HLA Ⅱ类免疫原性突变负担可预测免疫检查点阻断的反应。
Ann Oncol. 2022 Jul;33(7):728-738. doi: 10.1016/j.annonc.2022.03.013. Epub 2022 Mar 23.
6
Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy.全身炎症指数和肿瘤糖酵解异质性有助于对接受酪氨酸激酶抑制剂治疗的晚期表皮生长因子受体突变型肺腺癌患者进行风险分层。
Cancers (Basel). 2022 Jan 8;14(2):309. doi: 10.3390/cancers14020309.
7
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.针对具有致癌驱动分子改变的肺癌患者的靶向治疗。
J Clin Oncol. 2022 Feb 20;40(6):611-625. doi: 10.1200/JCO.21.01626. Epub 2022 Jan 5.
8
Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma.肿瘤糖酵解异质性提高肺腺癌患者区域淋巴结转移的检出率。
Ann Nucl Med. 2022 Mar;36(3):256-266. doi: 10.1007/s12149-021-01698-1. Epub 2021 Nov 24.
9
Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.四种程序性死亡配体 1(PD-L1)免疫组织化学检测方法在三阴性乳腺癌中的检测结果的批内和批间及观察者间可比性研究。
Breast. 2021 Dec;60:238-244. doi: 10.1016/j.breast.2021.11.003. Epub 2021 Nov 6.
10
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.分子和功能特征分析鉴定了浆母细胞淋巴瘤中有治疗靶向作用的脆弱性。
Nat Commun. 2021 Aug 31;12(1):5183. doi: 10.1038/s41467-021-25405-w.